메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY, Jan. 27, 2026 -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program. C
- 김갑성 기자
- 2026-01-27 21:00
스카이호크 테라퓨틱스, 헌팅턴병 치료제 SKY-0515 제1상 임상시험 환자 대상 9개월 중간 결과 발표

9개월 분석 결과 복합 통합 헌팅턴병 등급 척도가 기저치 대비 평균 0.64점 개선-성향 점수 가중치 적용 시 증상 발현 환자의 9개월 예상 자연 경과 악화 수치인 -0.73점 대비 스카이호크, SKY-0515의 임상 2/3상인 FALCON-HD 시험을 전 세계로 확대한다고 발표- 현재까지 90명 이상의 환자에게 투약 시행 보스턴, 2026년 1월 27일 -- 중요한 RNA 표적을 조절하는 혁신적 저분자 치료제를 개발 중인 임상 단계 바이오테크 기업 스카이호크 테라퓨틱스(Skyhawk Therapeutics, Inc.)가 1월 27일 자사의 헌팅턴병(Huntington's disease, HD) 임상시험 치료제인 SKY-0515의 9개월 중간 분석에서 긍정적인 결과가 도출됐다고 발표했다. SKY-0515 투여 결과 9mg 용량에서 혈액 내 변이 헌팅틴 단백질(mHTT)이 62% 감소하는 등 용량 의존적 감소가 나타났으며, 체세포 CAG 반복 확장 및 헌팅턴병 병리학의 핵심 동인인 PMS1 mRNA는 26% 감소했다. 또한 SKY-0515는 우수한 중추신경계 노출을 입증했으며 전반적으로 안전하
- 김갑성 기자
- 2026-01-27 21:00
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

[ 메디채널 김갑성 기자 ] Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset. Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million SHANGHAI, Jan. 27, 2026 -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a
- 김갑성 기자
- 2026-01-27 18:40
Libevitug Approved in China as First-in-Class Treatment for Hepatitis D

BEIJING, Jan. 27, 2026 -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for vir
- 김갑성 기자
- 2026-01-27 16:18
Libevitug Approved in China as First-in-Class Hepatitis D Treatment

BEIJING, Jan. 27, 2026 -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus (HBV) and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China's first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clini
- 김갑성 기자
- 2026-01-27 16:15
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Servier reported Group revenues of €6.9 billion for 2024/25, up 16.2% from 2023/24. Growth over the financial year was driven by increased sales in oncology, particularly in the United States. Several partnership agreements in oncology and neurology strengthen the Group's R&D portfolio in rare diseases. Achieving 2025 targets reflects successful transformation that began in 2015 and underpins the Group's ambitions for 2030. SURESNES, France, Jan. 27, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, published its financi
- 김갑성 기자
- 2026-01-27 16:00
3Shape appoints Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy

COPENHAGEN, Denmark, Jan. 27, 2026 -- 3Shape today announced the appointment of Rasmus Hannemann as Senior Vice President, Portfolio & Product Strategy, effective 9 March. Rasmus will step into the Senior Leadership Team and will report directly to CEO Jacob Paulsen. Rasmus joins 3Shape from Coloplast, where he spent more than 20 years in senior leadership roles spanning strategy, product management, marketing, and global business leadership. Most recently, he served as Vice President, Group Development & Strategy, with responsibility for corporate strategy, M&A, and post-m
- 김갑성 기자
- 2026-01-27 15:45
Getinge Q4 and Full-Year Report 2025: Organic growth and solid cash flow to end the year

GOTHENBURG, Sweden, Jan. 27, 2026 -- "We succeeded in growing organically, delivering a record-breaking fourth quarter and organic growth at the upper end of our forecast, 4.9% for the full year," says Mattias Perjos, President & CEO at Getinge. Higher demand for consumables for ECLS-therapy in the quarter and in Acute Care Therapies contributed to Getinge's performance. Sales were also strong in Transplant Care and ventilators. Surgical Workflows continued to strengthen its market-leading position in operating tables and enters 2026 with robust order bookings. In general
- 김갑성 기자
- 2026-01-27 15:23
Davos Spotlight | EVYD, Ministry of Health Brunei Darussalam and Novartis Foundation Launch National AI-Powered Cardiovascular Disease Prevention Initiative

DAVOS, Switzerland, Jan. 27, 2026 -- At the 2026 World Economic Forum Annual Meeting in Davos, Dr. Giovanni Caforio, Chairman of the Board of Directors of Novartis, announced a major new partnership: the Novartis Foundation, the Ministry of Health of Brunei Darussalam, and EVYD Technology will jointly implement an AI- and data-enabled national cardiovascular disease prevention initiative under the global program: CARDIO4Cities. Built on Brunei's national health platform, the program aims to harness population-scale data and artificial intelligence to enable early identification of high
- 김갑성 기자
- 2026-01-27 14:37
Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the maintenance treatment of chronic obstructive pulmonary disease

SHANGHAI, Jan. 27, 2026 -- Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease. Ohtuvayre® is a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 ("PDE3 and PDE4") that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule, delivered directly to the lungs through a standard jet nebulizer.&nbs
- 김갑성 기자
- 2026-01-27 10:13

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2026-03-03_TUE

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 03시 40분